Maravai Lifesciences Holdings Inc. (MAR)
XFRA 
Summary
MAR Chart
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Q1 Earnings Call Highlights
Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago.
Maravai Lifesciences Holdings Inc. (MAR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Maravai Lifesciences Holdings Inc. ever had a stock split?
Maravai Lifesciences Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bernd Brust CEO | XFRA Exchange | US56600D1072 ISIN |
| US Country | 570 Employees | - Last Dividend | - Last Split | 20 Nov 2020 IPO Date |
Overview
Maravai LifeSciences Holdings, Inc. is a prominent player in the life sciences industry, dedicated to providing a comprehensive range of products that facilitate the development of drug therapies, diagnostics, and novel vaccines, in addition to supporting research on human diseases on a global scale. Established in 2020 and based in San Diego, California, Maravai LifeSciences serves a diverse clientele that includes biopharmaceutical companies, life sciences research organizations, academic research institutions, and in vitro diagnostics companies. The company strategically operates through two main segments: Nucleic Acid Production and Biologics Safety Testing, catering to the critical phases of biopharmaceutical development with its innovative product offerings.
Products and Services
- Nucleic Acid Production
- Biologics Safety Testing
This segment is key to Maravai LifeSciences, providing essential products for gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. It includes the production and sale of reagents for the chemical synthesis, modification, labeling, and purification of DNA and RNA. Key offerings comprise messenger RNA, oligonucleotides, oligonucleotide building blocks, custom enzyme development and manufacturing, along with CleanCap capping technology, which is instrumental in the success of these revolutionary therapies and diagnoses.
Focusing on the safety aspect of biopharmaceutical production, this segment delivers analytical products designed for biologic manufacturing process development. It includes custom product-specific development, antibody and assay development services tailored to clients' needs. The segment also offers Host Cell Protein (HCP) ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and bespoke services. These products are crucial for ensuring the purity and efficacy of biopharmaceutical products by detecting impurities and contaminants during production stages.
